An analysis of 2 pharmacovigilance databases revealed a high prevalence of azacitidine-related adverse events in patients with MDS or AML.

Metformin, a widely used and affordable diabetes drug, could prevent a form of acute myeloid leukemia in people at high risk ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or ...

SELLAS Life Sciences (SLS) announced Cohort 3 data from the ongoing Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in ...

1Children’s Research Institute and the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas. 10Howard Hughes Medical Institute, UT Southwestern Medical Center, ...

Recent advancements in multi-omics technology have generated significant interest in exploring the role of gut microbiota in the treatment and prognosis of acute myeloid leukemia (AML ... function and ...

In 20 BTKi-experienced patients: 13 patients had change in tumor burden ... 1 CR and 4 PRs. TakeAim Leukemia In December 2024, the Company announced data from the TakeAim Leukemia study (NCT 04278768) ...

The proximal tubules and the myeloid cells were both positive for lysozyme (Figure 1C – 100x). 1. Attieh RM, Begum F, Chitty D, Izzedine H, Jhaveri KD. Kidney and urinary tract involvement in chronic ...